December 22nd 2021
From the approval of the first insulin glargine biosimilar (Semglee) to the potential for extreme biosimilar competition in the adalimumab market, 2021's regulatory stories were popular with readers.
December 21st 2021
By Tony Hagen
The year 2021 brought several firsts in biosimilars and set the stage for expansion across therapeutic areas including diabetes and ophthalmology.
December 16th 2021
Investigators said more evidence would help to convince clinicians of the safety of switching between biosimilar products.
December 11th 2021
Tot Biopharm receives China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for a Suzhou Innovation and Collaboration Center.
December 9th 2021
Ahead of sales and revenues, Icelandic company Alvotech lines up a massive capital investment and an initial public offering (IPO).
December 7th 2021
By Deana Ferreri, PhD
In a review, Sandoz researchers discuss lingering barriers that prevent insulin prices from falling to more affordable levels.
December 2nd 2021
By Meir Rinde, MS
Researchers report findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.
November 30th 2021
Regulators are at work clarifying biosimilar guidance and on Capitol Hill, a battle is raging over reforms that could help or hurt biosimilar advancement.
November 24th 2021
Authors of a new study estimated significant savings from biosimilars in Ontario based on deep price discounts and mandatory switching programs.
November 23rd 2021
Authors of a review discuss barriers to insulin access and potential solutions as the 100-year anniversary of the drug's first use for diabetes gets closer.
